炭疽疫苗市场- 按类型（无细胞PA 疫苗[吸收、沉淀]、减毒活疫苗）、应用（人类使用、兽医使用）、最终用途（兽医医院和诊所、医院和诊所）和预测（2024 年- 2032 年） ）

在疫苗生产投资增加的推动下，2024年至2032年全球炭疽疫苗市场复合年增长率将达到5.4%。各国政府和私部门利害关係人正在认识到，迫切需要有效接种炭疽疫苗，炭疽是一种严重的细菌感染，可用作生物恐怖主义武器。因此，大量资金被用于先进的炭疽疫苗研究、开发和製造。

例如，2024 年 1 月，美国国防部 (DoD) 授予 Emergent BioSolutions 一份价值高达 2.358 亿美元的采购合同，用于无限期交付和无限数量 (IDIQ) 供应 BioThrax。根据这份合同，Emergent 将向所有面临炭疽暴露高风险的美国军事人员提供 BioThrax。

不断增强的公共卫生意识和政府措施正在推动市场成长。投资不仅可以提高疫苗的可用性，还可以确保生产技术的改进、功效的提高和可及性的提高。此外，COVID-19 大流行凸显了强大的疫苗基础设施的重要性，促使人们进一步投资于能够生产各种疫苗（包括炭疽疫苗）的设施。因此，在旨在保障公众健康和国家安全的财政承诺的支持下，炭疽疫苗市场可望大幅成长。

炭疽疫苗产业的整体价值根据类型、应用、最终用途和地区进行分类。

2024 年至 2032 年，来自减毒活疫苗领域的炭疽疫苗市场收入将实现令人称讚的复合年增长率。它们的功效和诱导强大免疫反应的能力使它们备受追捧，特别是在炭疽暴露风险高的地区。对生物技术和先进疫苗生产技术的投资进一步提振了市场。减毒活疫苗为军事人员、农业工人和流行地区人群提供了可靠的解决方案，推动了炭疽疫苗市场的大幅成长。

从 2024 年到 2032 年，人类使用部分将显着成长。疫苗技术的进步和公众健康意识的提高导致对研究和生产的投资增加。此外，各国监管部门的批准和战略储备措施正在提振市场需求。因此，人用炭疽疫苗市场正在经历显着成长，确保做好准备并保障公众健康。

2024年至2032年，欧洲炭疽疫苗市场将呈现显着的复合年增长率。欧盟对疫苗研发的监管支持和资助正在进一步推动市场成长。此外，生物技术公司和公共卫生机构之间的合作正在提高疫苗的可用性和功效。这种积极主动的做法确保欧洲做好充分准备，减轻炭疽疫情的风险，进而推动炭疽疫苗市场的持续需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球炭疽病负担日益加重
    • 疫苗研发的技术进步
    • 全球化与旅行的增加
  • 产业陷阱与挑战
    • 缺乏对目标疾病诊断测试的认识
    • 疫苗成本高
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 无细胞PA疫苗
  • 炭疽疫苗吸收（AVA）
  • 炭疽疫苗沉淀 (AVP)
• 减毒活疫苗

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 兽医用途
• 人类使用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 兽医医院和诊所
• 医院及诊所
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Altimmune Inc.
• Agrovet
• Bayer AG
• Bavarian Nordic
• Biogenesis Bago SA
• Ceva Sante Animale
• Colondo Serum Company
• Emergent BioSolutions
• Elusys Therapeutics Inc.
• Indian Immunologicals Ltd.
• Intervac (PVT) Ltd
• JOVAC
• Merck Co, Inc.
• Proton Biopharma Ltd.

Global Anthrax Vaccine Market will witness 5.4% CAGR between 2024 and 2032, driven by increasing investments in vaccine production. Governments and private sector stakeholders are recognizing the critical need for effective vaccination against anthrax, a serious bacterial infection that can be used as a bioterrorism weapon. Consequently, significant funds are being directed towards research, development, and manufacturing of advanced anthrax vaccines.

For instance, in January 2024, The US Department of Defense (DoD) awarded Emergent BioSolutions a procurement contract valued at up to $235.8 million for an indefinite-delivery and indefinite-quantity (IDIQ) supply of BioThrax. Under this contract, Emergent will provide BioThrax to all US military personnel at high risk of anthrax exposure.

The growing public health awareness and government initiatives are fueling market growth. Investments are not only enhancing vaccine availability but also ensuring improved production techniques, higher efficacy, and greater accessibility. Additionally, the COVID-19 pandemic has underscored the importance of robust vaccine infrastructure, prompting further investments into facilities capable of producing a wide range of vaccines, including those for anthrax. As a result, the anthrax vaccine market is poised for substantial growth, underpinned by financial commitments aimed at safeguarding public health and national security.

The overall Anthrax Vaccine Industry value is classified based on the type, application, end-use, and region.

The anthrax vaccine market revenue from the live attenuated vaccine segment will register a commendable CAGR from 2024 to 2032. These vaccines, which contain a weakened form of the bacterium that causes anthrax, provide strong and long-lasting immunity. Their efficacy and ability to induce a robust immune response make them highly sought after, particularly in regions with high anthrax exposure risks. Investments in biotechnology and advanced vaccine production techniques have further bolstered the market. Live attenuated vaccines offer a reliable solution for military personnel, agricultural workers, and populations in endemic areas, driving substantial growth in the anthrax vaccine market.

The human use segment will witness an appreciable growth from 2024 to 2032. Governments and health organizations are prioritizing the vaccination of high-risk groups, such as military personnel and laboratory workers. Advances in vaccine technology and heightened public health awareness have led to increased investments in research and production. Furthermore, regulatory approvals and strategic stockpiling initiatives by various countries are bolstering market demand. As a result, the anthrax vaccine market for human use is experiencing significant growth, ensuring preparedness and safeguarding public health.

Europe anthrax vaccine market will exhibit a notable CAGR from 2024 to 2032. European governments are investing in advanced vaccine production and stockpiling to protect high-risk populations, such as military personnel and emergency responders. The European Union's regulatory support and funding for vaccine research and development are further propelling market growth. Additionally, collaborations between biotech companies and public health institutions are enhancing vaccine availability and efficacy. This proactive approach ensures Europe is well-prepared to mitigate the risks of anthrax outbreaks, driving sustained demand in the anthrax vaccine market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of anthrax globally
    • 3.2.1.2 Technology advancements in the vaccine development
    • 3.2.1.3 Increased globalization and travel
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness for diagnostic test of target disease
    • 3.2.2.2 High cost of vaccine
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cell free PA vaccine
  • 5.2.1 Anthrax vaccine absorbed (AVA)
  • 5.2.2 Anthrax vaccine precipitated (AVP)
• 5.3 Live attenuated vaccine

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Veterinary use
• 6.3 Human use

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Veterinary hospitals & clinics
• 7.3 Hospital & clinics
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Altimmune Inc.
• 9.2 Agrovet
• 9.3 Bayer AG
• 9.4 Bavarian Nordic
• 9.5 Biogenesis Bago SA
• 9.6 Ceva Sante Animale
• 9.7 Colondo Serum Company
• 9.8 Emergent BioSolutions
• 9.9 Elusys Therapeutics Inc.
• 9.10 Indian Immunologicals Ltd.
• 9.11 Intervac (PVT) Ltd
• 9.12 JOVAC
• 9.13 Merck Co, Inc.
• 9.14 Proton Biopharma Ltd.